About 3% of U.S. patients with metastatic pancreatic cancer survive five years. A drug pair starts testing in patients.
Revolution Medicines has initiated a Phase 3 clinical trial (RASolute 309) for a new first-line treatment for metastatic RAS G12D pancreatic adenocarcinoma, combining RASONQUE (daraxonrasib) and zoldonrasib. The trial aims to improve progression-free survival and overall survival compared to standard chemotherapy, addressing a cancer with a very low five-year survival rate. RASONQUE is already FDA-approved for previously treated metastatic pancreatic cancer, while zoldonrasib is investigational.
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Revolution Medicines has initiated patient treatment in its Phase 3 RASolute 309 clinical trial. This trial evaluates RASONQUE™ (daraxonrasib) combined with zoldonrasib as a first-line therapy for metastatic RAS G12D pancreatic adenocarcinoma. The company aims to address the significant unmet medical need for patients with this aggressive form of cancer, leveraging their RAS(ON) inhibitor platform.
Revolution Medicines (RVMD) Could Be 8% Overvalued As FTSE All World Inclusion Draws Focus
Revolution Medicines (RVMD) was recently added to the FTSE All-World Index, attracting attention, but its current trading price of US$205.89 suggests it might be 8% overvalued according to some analysts, who set its fair value at $190.52. In contrast, Simply Wall St's DCF model indicates the stock could be significantly undervalued, with a future cash flow value of $857.71. This divergence highlights mixed perspectives on whether the market is adequately pricing in execution risks or underestimating the company's potential in RAS-driven cancers.
Revolution Medicines’ CDO Sandler sells $1.2m in stock
Alan B. Sandler, Chief Development Officer at Revolution Medicines, Inc., sold 6,309 shares of the company’s common stock for $1,275,294 and acquired 6,000 shares by exercising stock options for $353,040. These transactions were executed under a 10b5-1 trading plan. The sale occurs as the stock, which has surged 349% in the past year, is considered overvalued by InvestingPro analysis, despite the company's strong financial position.
Revolution Medicines’ CDO Sandler sells $1.2m in stock By Investing.com
Alan B. Sandler, Chief Development Officer at Revolution Medicines, sold over $1.2 million worth of company stock but also acquired 6,000 shares through stock options. This comes as the company's stock has surged by 349% over the past year, although InvestingPro analysis suggests it may be overvalued. The company recently received FDA approval for its drug Rasonque, leading to positive analyst outlooks and raised price targets from several financial firms.
This Pill Will Change Cancer Treatment Forever
Revolution Medicines' drug, Rasonque (daraxonrasib), has received FDA approval as the first broad-spectrum treatment for RAS-mutated pancreatic cancer. In clinical trials, it doubled the median survival rate for patients with metastatic pancreatic ductal adenocarcinoma compared to standard chemotherapy. This breakthrough offers a significant new treatment option for a cancer previously considered untreatable, with potential future applications for other RAS-driven cancers.
6,000 shares from exercised options are listed for an officer’s proposed sale at Revolution Medicines (RVMD).
Revolution Medicines (RVMD) officer Alan Sandler has proposed to sell 6,309 common shares valued at approximately $1.27 million, with an approximate sale date of September 29, 2026. This proposed sale includes 6,000 shares from stock-option exercises and 309 shares from restricted stock units. The company's latest SEC filing also noted the sale of 341 common shares by Sandler in the preceding three months, totaling $67,940.67.
Revolution Medicines SVP Jeff Cislini Sells 765 Shares Under 10b5-1 Trading Plan
Jeff Cislini, SVP and General Counsel of Revolution Medicines, Inc. (NASDAQ: RVMD), sold 765 shares of company stock on September 25, 2026, at $207.3201 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on May 22, 2026. Following the sale, Cislini directly owns 51,776 shares, including restricted stock units.
Revolution Medicines SVP Cislini sells $158,599 in shares
Jeff Cislini, SVP and General Counsel at Revolution Medicines, sold 765 shares worth $158,599 on September 25, 2026, under a pre-arranged trading plan. This sale follows a significant increase in the company's stock price over the past year. The article also highlights recent positive news for Revolution Medicines, including FDA approval for its drug Rasonque and upgraded price targets from several financial institutions.
Form 4 Revolution Medicines Inc For: 29 September By Investing.com
This article reports on a Form 4 filing for Revolution Medicines Inc, specifically related to activity on September 29. It appears to be a standard financial markets news brief from Investing.com, providing basic information about the regulatory filing.
Does Rasonque Launch Change The Bull Case For Revolution Medicines Stock?
Revolution Medicines, recently added to the FTSE All-World Index, is preparing for the commercial launch of Rasonque for second-line pancreatic cancer. This shift from pure R&D to initial commercialization raises key questions for investors regarding sales force efficiency and market demand, especially given the company's current pre-revenue status and high operating expenses. Analysts project significant revenue and earnings growth by 2029, though various fair value estimates suggest both potential upside and downside to its current stock price.
Does Rasonque Launch Change The Bull Case For Revolution Medicines Stock?
Revolution Medicines is preparing for the commercial launch of Rasonque, a RAS-focused oncology drug, in second-line pancreatic cancer. This marks a shift from significant R&D spending to an initial commercial footing, with analysts projecting substantial revenue growth and a swing to profitability by 2029. The success of this launch and the company's ability to scale its sales force efficiently will be crucial for its investment narrative.
Revolution Medicines officer Mancini sells $743k in stock
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc. (NASDAQ:RVMD), recently sold common stock worth $743,285 through transactions executed on September 24 and 25, 2026. The sales were part of a pre-arranged 10b5-1 trading plan. Despite the insider sales, the company's stock has shown exceptional returns, surging 359% over the past year, following the FDA approval of its drug Rasonque for treating metastatic pancreatic cancer.
Form 4 Revolution Medicines Inc For: 28 September By Investing.com
This article reports on a Form 4 filing for Revolution Medicines Inc. on September 28, 2026. It includes basic stock information for RVMD and is part of a financial news platform providing market data and analysis.
Brookline initiates Revolution Medicines stock with buy rating
Brookline Capital Markets has initiated coverage on Revolution Medicines Inc. (NASDAQ:RVMD) with a Buy rating and a $318 price target. The company, which recently launched its first product Rasonque for RAS-addicted cancers, is projected to see significant revenue growth, reaching $59.5 billion by 2033. Despite an InvestingPro analysis suggesting the stock is currently overvalued, the firm believes Revolution Medicines has strong liquidity and sufficient cash to fund its development to profitability.
Form 144 REVOLUTION MEDICINES INC For: 27 September By Investing.com
This article announces the filing of Form 144 for REVOLUTION MEDICINES INC on September 27. It is a brief financial news item from Investing.com, providing information relevant to stock market observers. The article itself contains no further details beyond the announcement of the filing.
How a UCSF scientist's persistence led to a $1 million prize and groundbreaking cancer drug
Kevan Shokat, a professor at UCSF and co-founder of Revolution Medicines Inc., has won a $1 million prize for his work on Rasonque, a pancreatic cancer drug. Shokat is a Howard Hughes investigator and a key scientific figure behind several biotech companies. This award recognizes his persistence and contributions to groundbreaking cancer research.
Revolution Medicines Receives FDA Breakthrough Designation, Royalty Pharma Offers a Diversified Investment Path
Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its metastatic pancreatic cancer drug RASONQUE, causing its stock to rise significantly. For investors seeking exposure to such pharmaceutical successes while diversifying risk, Royalty Pharma (RPRX) offers an alternative by investing in drug royalties across multiple companies, including RASONQUE. Royalty Pharma provides a safer investment path with a diversified portfolio and dividend income, contrasting with the higher-risk, higher-reward profile of holding a single stock like Revolution Medicines.
Stock options are the source of 9,363 shares a Revolution Medicines (RVMD) officer proposes to sell.
Anthony Mancini, an officer at Revolution Medicines, Inc. (RVMD), has proposed selling 9,363 common shares valued at approximately $1.87 million, with an anticipated sale date of September 25, 2026. These shares are linked to stock-option exercises expected to occur over the next three months. The filing, categorized as a Form 144, has a neutral impact and sentiment according to the analysis.
Revolution Medicines director Elizabeth Anderson sells $1.96m in stock
Elizabeth M. Anderson, a director at Revolution Medicines, Inc. (NASDAQ:RVMD), sold approximately $1.96 million worth of stock on September 22, 2026, following the exercise of stock options. This sale was conducted under a pre-arranged 10b5-1 trading plan. The company's stock has seen a significant surge, and its new drug, Rasonque, recently received FDA approval, leading to increased price targets from several analysts.
Revolution Medicines Gains as New Buy Rating Adds to Recent Regulatory Momentum
Revolution Medicines (RVMD) saw a 4.8% increase in its stock price, largely attributed to a new "Buy" rating from Goldman Sachs, which highlighted confidence in the company's oncology platform. This momentum is further bolstered by the FDA's recent Breakthrough Therapy Designation for RASONQUE in metastatic pancreatic cancer, signaling the company's transition into a commercial-stage oncology firm. The article also details recent insider trading activity, institutional holdings, and analyst price targets for RVMD.
After three earlier sales, an officer proposes selling 587 more Revolution Medicines (RVMD) shares.
Revolution Medicines (RVMD) officer Anthony Mancini has proposed selling 587 common shares, valued at $111,964.38, through Morgan Stanley Smith Barney LLC on September 24, 2026. This proposed sale follows three prior common-stock sales by Mancini in September 2026, totaling 18,986 shares, with two of these earlier sales identified as 10b5-1 sales. The article details the specific dates, share counts, and aggregate market values of both the proposed and previous sales.
Client Revolution Medicines Secures 672,000-Square-Foot Redwood City Lease in former Google Space
Procopio client Revolution Medicines, Inc. has secured a lease for approximately 672,000 square feet at Pacific Shores Center in Redwood City, California, formerly occupied by Google. This expansion will nearly double the biotechnology company's local footprint. The transaction, facilitated by Procopio, comes shortly after Revolution Medicines achieved a major milestone with FDA approval for RASONQUE™ (daraxonrasib), marking its transition to a commercial-stage oncology company.
Revolution Medicines officer sells $353,449 in shares
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, sold 1,774 shares of common stock worth $353,449 on September 16, 2026, to cover tax obligations. The company's stock has seen significant growth, surging over 322% in the past year, and recently received FDA approval for its drug Rasonque, leading to revised price targets from several financial institutions.
Revolution Medicines senior advisor Stephen Kelsey disposes of $18.7m in shares
Stephen Kelsey, a Senior Advisor at Revolution Medicines, has disposed of approximately $18.7 million worth of company common stock through pre-arranged trading plans. Concurrently, he acquired shares worth about $3.86 million by exercising stock options, also under the same trading plan. These transactions follow a significant 358% surge in Revolution Medicines shares over the past year, and coincide with recent FDA approval for its drug Rasonque, which has led to several analysts revising their price targets upwards.
Revolution Medicines to anchor former Google campus as Silicon Valley office market shifts
Revolution Medicines has secured a lease for 672,000 square feet at the Pacific Shores Center in Redwood City, formerly a Google campus. This deal marks Silicon Valley's second-largest office lease this year and signifies a trend of investors repurposing older tech campuses for new tenants. The move highlights a shift in the Silicon Valley office market.
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Revolution Medicines has received Breakthrough Therapy Designation from the U.S. FDA for RASONQUE™ (daraxonrasib) in combination with chemotherapy for first-line metastatic pancreatic cancer. This designation, the fifth for their RAS(ON) inhibitors, highlights RASONQUE's potential to address the significant unmet medical needs in patients with previously untreated metastatic pancreatic adenocarcinoma. The designation is based on encouraging preliminary antitumor activity and a manageable safety profile observed in clinical trials.
Revolution Medicines director Lorence Kim sells $3.58m in stock
Lorence H. Kim, a director at Revolution Medicines, Inc. (NASDAQ:RVMD), sold 17,190 shares of common stock totaling $3,585,836 on September 8, 2026, through a 10b5-1 trading plan. These sales occurred at weighted average prices ranging from $206.6049 to $212.2693, following a significant surge in the company's stock price. After these transactions, the Lorence Kim Revocable Trust no longer holds shares, though Kim retains 1,191 shares directly, including restricted stock units.
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) shares have risen 6.6% since its last earnings report, outperforming the S&P 500. However, the company reported a wider-than-expected Q2 2026 loss with no revenues, and its operating expense outlook for 2026 has increased significantly. Analyst estimates have shown a downward trend, leading to a Zacks Rank #3 (Hold) for the stock.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
Revolution Medicines (NASDAQ: RVMD) recently received FDA approval for RASONQUE, a broad RAS-targeted therapy for metastatic pancreatic cancer, a significant medical breakthrough that nearly doubled median overall survival in trials. Despite the breakthrough, the stock's price remained relatively flat on the news, as the approval was largely "priced in" after a 41% surge when trial data was initially presented months prior. The company now faces the challenge of commercial execution, with rising operating expenses and a widened net loss, making successful market penetration and label expansion critical for its future stock performance.
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Revolution Medicines announced that The New England Journal of Medicine has published Phase 1/2 clinical data for RASONQUE (daraxonrasib) in patients with metastatic non-small cell lung cancer (NSCLC) harboring diverse RAS mutations. The data supports the ongoing Phase 3 RASolve 301 trial, demonstrating dose-dependent antitumor activity and a manageable safety profile, particularly in a subgroup of docetaxel-naïve patients. RASONQUE is an oral, RAS(ON) multi-selective inhibitor, already FDA-approved for metastatic pancreatic adenocarcinoma.
Why Revolution Medicines, the Drugmaker Behind a Pancreatic Cancer Breakthrough, Stayed Independent
Revolution Medicines, a biotech company, chose to remain independent despite takeover interest, a decision that proved successful with the FDA approval of its pancreatic cancer pill, Rasonque (daraxonrasib). The company, which previously had no drugs on the market, focused on promising research that has now led to a significant breakthrough for adults with metastatic pancreatic cancer.
Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
Revolution Medicines' new pancreatic cancer drug, Rasonque, is projected to become a blockbuster with sales potentially reaching $15.1 billion by 2034 for pancreatic cancer alone, and up to $20.8 billion with additional cancer approvals. This optimistic forecast is driven by its higher-than-expected list price of $39,800 per month and a broad FDA approval that allows for flexible use, potentially even as a first-line treatment. Analysts are calling its launch "transformative/historic" due to its scientific breakthrough nature and ability to extend survival in a deadly cancer.
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The U.S. FDA has approved Revolution Medicines' RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma, marking the first broad RAS-targeted medicine for this challenging cancer. The approval is based on the Phase 3 RASolute 302 trial, where RASONQUE significantly reduced the risk of death by 60% and demonstrated improved overall survival and quality of life compared to chemotherapy. The drug is now available in the U.S. and represents a monumental step forward in treating RAS-addicted cancers.
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage
Revolution Medicines' CEO Mark Goldsmith anticipates quick coverage from insurers for their new $39,800-monthly Rasonque drug, approved for advanced pancreatic cancer. The drug, which reduced the risk of death by 60% in trials, has led RBC Capital to raise its target price for RVMD and expect a rapid commercial rollout due to limited alternatives for patients. Retail sentiment for RVMD has also turned "extremely bullish" following the news.
F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
The FDA has approved a new drug, daraxonrasib, made by Revolution Medicines, for advanced pancreatic cancer. The drug, sold as Rasonque, is taken as two pills a day and has shown significant improvement in life expectancy, doubling it in clinical trials for patients with metastatic pancreatic cancer who have already undergone chemotherapy. While not a cure, it marks a substantial advancement in treating a historically challenging disease, with a monthly sticker price of $39,800, largely expected to be covered by insurance.
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
The FDA has approved Revolution Medicines' drug, Rasonque (daraxonrasib), for adults with metastatic pancreatic cancer who have received prior treatment or cannot undergo combination chemotherapy. This once-daily pill targets the RAS protein, which is known to drive tumor growth. Clinical trials showed that the drug significantly improved overall survival to 13.2 months compared to 6.7 months with standard chemotherapy.
Revolution Medicines(RVMD.US) Officer Sells US$17.99 Million in Common Stock
An officer at Revolution Medicines (RVMD.US) has sold common stock totaling US$17.99 million. This transaction indicates a significant insider sale at the company.
Revolution Medicines (RVMD) GC trades 56K shares via 10b5-1 plan
Revolution Medicines' General Counsel, Jeff Cislini, exercised stock options for 56,280 shares and subsequently sold 56,894 shares of common stock on August 21, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved sales at weighted average prices ranging from approximately $206.76 to $212.74 per share. Cislini still holds 43,514 restricted stock units after these transactions.
Revolution Medicines (RVMD) CEO trades stock under preset 10b5-1 plan
Revolution Medicines (RVMD) CEO Mark A. Goldsmith exercised options for 80,000 shares and subsequently sold 86,000 shares of common stock, including through revocable trusts, under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2026. The sales occurred at weighted average prices between $206.78 and $212.74, while the options were exercised at $4.73 per share. Goldsmith's reported holdings still include 182,938 restricted stock units.
ETFs Investing in Revolution Medicines, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Revolution Medicines, Inc. For each ETF, it provides details such as market value, weight of Revolution Medicines, Inc. stock, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs cover a range of market segments including total market, small-cap, mid-cap, large-cap, health care, and biotechnology.
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade
Revolution Medicines, Inc. director Mark A. Goldsmith plans to sell 80,000 shares of common stock on August 21, 2026, with an aggregate market value of approximately $16.9 million. This planned sale is linked to the exercise of stock options. In the preceding three months, Goldsmith sold 10,020 shares on June 16, 2026, for proceeds of over $1.5 million.
Revolution Medicines is about to double its space at a waterfront campus that once housed Google
Revolution Medicines, a fast-growing biotech company, is planning to significantly expand its Redwood City operations by doubling its space at the Pacific Shores campus, which previously housed Google. This expansion, involving a new lease for 700,000 square feet, is intended to support the commercial launch of its pancreatic cancer drug. The company has already seen nearly a fivefold growth in its Redwood City presence since 2020.
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus
Revolution Medicines, a rapidly expanding biotech company, is reportedly close to securing a lease for a 700,000-square-foot campus in Redwood City. This new facility, previously a Google outpost, would support the company's significant growth since 2020 and its plans for the commercial launch of its pancreatic cancer drug. The move highlights the increasing demand for premium office space in Silicon Valley.
Revolution Medicines (NASDAQ: RVMD) trust to sell 3,000 shares under Rule 144
The Rebecca Goldsmith Revocable Trust intends to sell 3,000 shares of Revolution Medicines (RVMD) common stock under Rule 144. The aggregate market value of this proposed sale is approximately $635,205.00. This filing follows a previous sale of 10,020 shares by Mark A. Goldsmith, trustee for the trust, on June 16, 2026.
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale
Jeffrey Todd Cislini, a holder of Revolution Medicines (NASDAQ: RVMD), plans to sell up to 75,894 shares of common stock, valued at over $16 million, through Morgan Stanley Smith Barney LLC on or after August 21, 2026. The shares include those underlying restricted stock units and stock options. RVMD had 214,336,418 shares outstanding at the time of the filing.
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151
Bernstein has increased its target price for Revolution Medicines, Inc. (RVMD.O) to $179 from $151. This update, reported by Reuters, indicates a positive reevaluation of the company's stock outlook by the analyst firm.
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW
This article provides financial data for Revolution Medicines, Inc. (NASDAQ:RVMDW), specifically focusing on its enterprise value to revenue forward. It appears to be a financial snapshot from TradingView, displaying key company information.
Revolution Medicines (RVMD) Is Up 5.1% After Offloading Phase 3 Costs to BeOne Medicines
Revolution Medicines (RVMD) saw a 5.1% stock increase after partnering with BeOne Medicines. This collaboration shifts the financial burden of a global Phase 3 study for one of Revolution's RAS(ON) inhibitors to BeOne, while also granting BeOne regional commercialization rights in certain Asian markets. Despite this positive development, Revolution Medicines continues to face significant losses, emphasizing the need for their late-stage programs to gain approval and generate revenue.
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW
This article displays a financial metric, "Price to book forward," for Revolution Medicines, Inc. (NASDAQ: RVMDW). The content primarily serves as a placeholder for financial data, indicating that there are no active trades or specific values to show at the time of publication, suggesting a focus on providing real-time financial information when available.
